SI1803468T1 - Sredstva za zdravljenje glavkomatozne retinopatije in optične nevropatije - Google Patents

Sredstva za zdravljenje glavkomatozne retinopatije in optične nevropatije

Info

Publication number
SI1803468T1
SI1803468T1 SI200431767T SI200431767T SI1803468T1 SI 1803468 T1 SI1803468 T1 SI 1803468T1 SI 200431767 T SI200431767 T SI 200431767T SI 200431767 T SI200431767 T SI 200431767T SI 1803468 T1 SI1803468 T1 SI 1803468T1
Authority
SI
Slovenia
Prior art keywords
agents
optic neuropathy
retinopathy
nrf2
metabolites
Prior art date
Application number
SI200431767T
Other languages
English (en)
Inventor
Robert Landers
Iok-Hou Pang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1803468T1 publication Critical patent/SI1803468T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
SI200431767T 2003-12-22 2004-12-17 Sredstva za zdravljenje glavkomatozne retinopatije in optične nevropatije SI1803468T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53177003P 2003-12-22 2003-12-22
EP07105047A EP1803468B1 (en) 2003-12-22 2004-12-17 Agents for treatment of glaucomatours retinopathy and optic neuropathy

Publications (1)

Publication Number Publication Date
SI1803468T1 true SI1803468T1 (sl) 2011-12-30

Family

ID=34738696

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200430296T SI1696958T1 (sl) 2003-12-22 2004-12-17 Sredstva za zdravljenje glavkomatozne retinopatije in optične nevropatije
SI200431767T SI1803468T1 (sl) 2003-12-22 2004-12-17 Sredstva za zdravljenje glavkomatozne retinopatije in optične nevropatije

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200430296T SI1696958T1 (sl) 2003-12-22 2004-12-17 Sredstva za zdravljenje glavkomatozne retinopatije in optične nevropatije

Country Status (20)

Country Link
US (2) US20050137146A1 (sl)
EP (2) EP1803468B1 (sl)
JP (2) JP4755599B2 (sl)
KR (1) KR20060127043A (sl)
CN (1) CN1897972A (sl)
AT (2) ATE357932T1 (sl)
AU (1) AU2004308919B2 (sl)
BR (1) BRPI0417987A (sl)
CA (1) CA2547852A1 (sl)
CY (2) CY1106623T1 (sl)
DE (1) DE602004005617T2 (sl)
DK (2) DK1803468T3 (sl)
ES (2) ES2282926T3 (sl)
HK (2) HK1097179A1 (sl)
MX (1) MXPA06006980A (sl)
PL (2) PL1696958T3 (sl)
PT (2) PT1696958E (sl)
SI (2) SI1696958T1 (sl)
WO (1) WO2005063295A1 (sl)
ZA (1) ZA200604862B (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881198B2 (en) * 2001-01-09 2005-04-19 J. David Brown Glaucoma treatment device and method
PT1696958E (pt) * 2003-12-22 2007-06-04 Alcon Inc Agentes para o tratamento de retinopatia glaucomatosa e neuropatia óptica .
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
WO2006030907A1 (ja) * 2004-09-16 2006-03-23 Redox Bioscience Inc. 網膜保護剤
WO2007035356A2 (en) * 2005-09-16 2007-03-29 Bg Implant, Inc. Glaucoma treatment devices and methods
WO2008016095A1 (fr) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2010505958A (ja) * 2006-10-10 2010-02-25 バーンハム インスティトゥート フォー メディカル リサーチ 神経防護作用組成物および方法
JP2008247898A (ja) * 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
CA2721666C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
RU2472475C2 (ru) * 2010-04-20 2013-01-20 Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) Способ комбинированного лечения глаукомной оптической нейропатии
US20130288985A1 (en) * 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
RU2447864C1 (ru) * 2010-09-15 2012-04-20 Инна Витальевна Щербинина Способ лечения заболеваний зрительного нерва и сетчатки
US9527817B2 (en) 2011-06-21 2016-12-27 The Johns Hopkins University Compounds for treating peripheral; neuropathies and other neurodegenerative; disorders
RU2546019C2 (ru) * 2013-03-02 2015-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения глаукомной оптической нейропатии
JP6340673B2 (ja) 2013-05-02 2018-06-13 レティナ ファウンデーション オブ ザ サウスウエストＲｅｔｉｎａ Ｆｏｕｎｄａｔｉｏｎ Ｏｆ Ｔｈｅ Ｓｏｕｔｈｗｅｓｔ 二層型眼用インプラント
CN107530189B (zh) 2014-12-31 2021-06-22 迈克罗欧普提克斯股份有限公司 青光眼治疗装置和方法
WO2017059272A1 (en) 2015-09-30 2017-04-06 Microoptx Inc. Dry eye treatment devices and methods
EP3509641A1 (en) 2016-09-12 2019-07-17 ST IP Holding AG Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
EP3509642A1 (en) 2016-09-12 2019-07-17 ST IP Holding AG Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
RU2647324C1 (ru) * 2017-04-24 2018-03-15 Игорь Евгеньевич Хаценко Способ определения показаний для лечения амблиопии с помощью нейропептидного препарата
BR112022018193A2 (pt) * 2020-03-30 2022-10-25 Wuhan Neurophth Biotechnology Ltd Company Vetor de expressão do fator 2 relacionado ao fator nuclear e2 humano e aplicação do vetor de expressão
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5571523A (en) * 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
AU689036B2 (en) * 1995-05-10 1998-03-19 Kureha Chemical Industry Co., Ltd. Pharmaceutical composition containing substance inhibiting HSP47 production
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
US6271224B1 (en) * 1995-12-21 2001-08-07 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
ES2205166T3 (es) * 1996-02-02 2004-05-01 D. Western Therapeutics Institute Derivados de isoquinolina y medicamento.
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JP3872834B2 (ja) * 1996-03-04 2007-01-24 第一製薬株式会社 メイラード反応抑制剤
NZ513800A (en) * 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
KR100543151B1 (ko) * 1997-01-16 2006-01-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 산화방지제와의 상승적인 상호작용을 통해 폴리시클릭 페놀계화합물의 세포 보호 효과를 증강시키는 조성물
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6441033B1 (en) * 1997-12-22 2002-08-27 Alcon Manufacturing, Ltd. 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
AU2440599A (en) * 1998-02-25 1999-09-15 Shionogi & Co., Ltd. Therapeutic agent for complication of diabetes
US20010041174A1 (en) * 1998-11-24 2001-11-15 Najam Sharif Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases
US6020383A (en) * 1999-01-11 2000-02-01 Eastman Chemicals Company Method for reducing blood cholesterol and/or blood triglycerides
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
GB0030727D0 (en) * 2000-12-15 2001-01-31 Lumitech Uk Ltd Methods and kits for detecting kinase activity
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
CA2357265C (en) * 2001-04-24 2004-04-13 University Of British Columbia Improved additive for livestock feeds
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
TWI335221B (en) * 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US7199122B2 (en) * 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
US7407986B2 (en) * 2001-12-18 2008-08-05 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
WO2003068202A1 (en) * 2002-02-15 2003-08-21 Dsm Ip Assets B.V. Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
US20030219846A1 (en) * 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
EP1545493A4 (en) * 2002-08-05 2006-01-11 Wackvom Ltd METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NEOVASCULARIZATION
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
CA2548146A1 (en) * 2003-12-22 2005-07-14 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
PT1696958E (pt) * 2003-12-22 2007-06-04 Alcon Inc Agentes para o tratamento de retinopatia glaucomatosa e neuropatia óptica .

Also Published As

Publication number Publication date
BRPI0417987A (pt) 2007-04-27
EP1696958B1 (en) 2007-03-28
ES2371364T3 (es) 2011-12-30
CA2547852A1 (en) 2005-07-14
HK1097179A1 (en) 2007-06-22
JP4755599B2 (ja) 2011-08-24
WO2005063295A1 (en) 2005-07-14
CY1106623T1 (el) 2012-01-25
PT1803468E (pt) 2011-11-23
ES2282926T3 (es) 2007-10-16
US20050137146A1 (en) 2005-06-23
PL1696958T3 (pl) 2007-08-31
EP1696958A1 (en) 2006-09-06
DE602004005617T2 (de) 2007-12-13
EP1803468A1 (en) 2007-07-04
DK1696958T3 (da) 2007-07-09
AU2004308919B2 (en) 2009-11-12
KR20060127043A (ko) 2006-12-11
MXPA06006980A (es) 2006-12-14
US20110144127A1 (en) 2011-06-16
HK1110772A1 (en) 2008-07-25
ATE523208T1 (de) 2011-09-15
CN1897972A (zh) 2007-01-17
CY1112393T1 (el) 2015-12-09
PT1696958E (pt) 2007-06-04
JP2007515423A (ja) 2007-06-14
DE602004005617D1 (de) 2007-05-10
ZA200604862B (en) 2007-10-31
SI1696958T1 (sl) 2007-08-31
EP1803468B1 (en) 2011-09-07
DK1803468T3 (da) 2011-12-05
ATE357932T1 (de) 2007-04-15
JP2011046736A (ja) 2011-03-10
AU2004308919A1 (en) 2005-07-14
PL1803468T3 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
HK1110772A1 (en) Agents for treatment of glaucomatours retinopathy and optic neuropathy
PT762837E (pt) Processo para melhorar a durabilidade e/ou estabilizacao de produtos degradaveis microbiologicamente
DK1572127T3 (da) Enzymbehandling af fødevarer til cøliaki
NO20034094D0 (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
EP1719410A4 (en) METHOD FOR COMBATING PLANT HEALTH DAMAGE THROUGH THE USE OF BACILLUS AND A COMBUSTION AGENT
ATE369372T1 (de) 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
BR0014214A (pt) Imidazoquinolinas substituìdas com amida
BRPI0417996A (pt) agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
NO20033664L (no) Mikroorganisme for biologisk detoksifisering av mykotoksiner, dvs okratoksiner og/eller zearleoner, så vel som fremgangsmåte og anvendelsederav
EP0858996A4 (en) AGENT FOR PROTECTING NERVOUS CELLS
WO2005048920A3 (en) Methods and compositions for protecting against cataract development associated with vitrectomies
AR032548A1 (es) Metodo y composicion para desinfectar una superficie contaminada con una proteina prion
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
ES2036238T3 (es) Derivados de hidroxietil-azolilo.
ATE526992T1 (de) Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung
AR034508A1 (es) Agente protector de las neuronas retinales.
GT200000136A (es) Gen de streptomyces avermitilis que dirige la relacion de avermectinas b2 : b1 (2).
ES2062570T3 (es) L-alfa-glicerofosforil-d-mio-inositol para el tratamiento de neuropatias perifericas y de cerebropatias.
BR0313543A (pt) 2,3-diidro-isoindol-1-onas com atividade de inibição de mao-b
BR0215752A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
ES2093054T3 (es) Antibioticos ab-023 y procedimiento para su preparacion.
UY27931A1 (es) 2,3-dihidro-isoindol-1-onas
ECSP993087A (es) Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas
AR042210A1 (es) Composicion farmaceutica que contiene antagonistas de leucotrienos b4 (ltb4) e inhibidores de la ciclooxigenasa (cox)